Dr. Hsien-Yuan Lane from China Medical University Hospital and Professor LIN, CHIEH HSIN from Kaohsiung Chang Gung Memorial Hospital have developed a novel antidepressant therapy based on sodium benzoate. This innovative approach diverges from traditional antidepressant hypotheses and is the first in the world to use a D-amino acid oxidase (DAAO) inhibitor for treating depression. Preliminary clinical trials have demonstrated outstanding efficacy and high safety, positioning sodium benzoate as a potential next-generation antidepressant.
Widespread Impact of Depression and Limitations of Current Treatments
According to the World Health Organization, approximately 280 million people worldwide suffer from depression. By 2030, depression is projected to become the leading global health burden. Current antidepressants, predominantly based on the monoamine theory, typically take 4 to 6 weeks to show effects, and about 30% to 60% of patients do not respond adequately. Additionally, depression is a severe neurological disorder that often impairs cognitive function and increases perceived stress. This heightened stress perception occurs even without an increase in actual environmental stressors. However, existing treatments have limited efficacy in alleviating perceived stress and cognitive impairment. Moreover, they are associated with side effects such as gastrointestinal discomfort, insomnia, and elevated low-density lipoprotein (LDL) cholesterol, further reducing patient adherence to therapy. The urgent need for novel, more effective, and safer antidepressants cannot be overstated.
Unique Mechanism of Sodium Benzoate Demonstrates Significant Clinical Efficacy
The development of this novel antidepressant centers on sodium benzoate, a DAAO inhibitor that increases the concentration of D-amino acids (e.g., D-serine) in synaptic spaces, enhancing NMDA neurotransmission. Sodium benzoate also functions as an antioxidant, boosting endogenous antioxidant activity and reducing oxidative stress. Both NMDA receptor dysfunction and oxidative stress are closely linked to the pathophysiology of depression.
To validate its efficacy, the research team conducted a randomized, double-blind clinical trial comparing sodium benzoate with sertraline and a placebo. After eight weeks of treatment, sodium benzoate demonstrated superior results in reducing perceived stress and improving cognitive function. Its efficacy surpassed that of both the placebo and sertraline, a commonly used selective serotonin reuptake inhibitor (SSRI). Furthermore, sodium benzoate exhibited a remarkable safety profile, with no adverse effects on cholesterol levels (in contrast to LDL elevation in the sertraline group) and the lowest trial dropout rates. Even among elderly patients, sodium benzoate showed excellent safety, tolerability, and consistency in effects.
Advancing Commercialization with Promising Market Potential
The development of sodium benzoate represents not only a groundbreaking therapeutic theory but also a significant achievement in clinical application, with excellent safety and international patent protection. It marks a breakthrough in psychiatry and psychopharmacology. Currently, the research institutions involved are negotiating technology transfer agreements to facilitate commercialization. Upon completion of further clinical trials, the new drug is projected to create a market value of approximately NT$1.5 billion in Taiwan, with global market potential estimated at $6 billion USD.
Dr. Lane stated that this innovative therapy offers a superior treatment option for depression patients and holds the potential to significantly reduce healthcare and medical costs.
Resource: DAAO抑制劑為基礎 「藥」抗憂鬱減輕感知壓力
